More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

U.S. President Donald Trump will meet on Thursday with chief executives from major drugmakers, a White House official ...

U.S. President Donald Trump is set to meet with top pharmaceutical executives on Thursday, a White House official confirmed. The discussions will focus on Medicare drug price negotiations, pharmacy ...

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

Healthcare costs and spending have been rising in the US. The Centers for Medicare & Medicaid Services reported that ...

Biosimilars have also made inroads among generic suppliers. But development is lengthy and expensive. McKinsey estimates that ...

While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

Novo Nordisk is seeking up to $830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as ...

The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...

NEW YORK, NY / ACCESS Newswire / February 17, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn ...

The manufacturer of the weight loss jab Wegovy has been reprimanded for allegedly failing to disclose or accurately report ...